Dr. M. Shaalan Beg joined the Division of Hematology/Medical Oncology specializing in cancers of the gastrointestinal tract. After receiving his medical training at the Aga Khan University in Karachi, Pakistan, he proceeded to complete his Internal Medicine residency and Hematology/Medical Oncology fellowship at the University of Cincinnati.
Dr. Beg’s clinical and research focus is on early-phase drug development and clinical trials for gastrointestinal cancers. He is an active member of the GI Cancers Disease Oriented Team and believes in true multidisciplinary care of his patients.
- Medical School
- Aga Khan Univ, Pakistan (2003)
- University of Cincinnati College of Medicine (2008), Internal Medicine
- University of Cincinnati (2011), Hematology Oncology
- Cancers of the gastrointestinal tract
- Early phase drug development, Phase I/II clinical trials
- Experimental therapeutics
- Peritoneal diseases
- Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data.
- Komrokji RS, Al Ali NH, Beg MS, Safa MM, Rollison D, Kharfan-Dabaja M, Bello C, Cultrera J, Sokol L, Pinilla-Ibarz J, Sotomayor EM Clin Lymphoma Myeloma Leuk 2011 Jun 11 3 257-60
- Outcome of esophageal carcinoma in the veteran affairs population: a comparative analysis from the Veteran Affairs Central Cancer Registry.
- Beg MS, Navaneethan U, Atiq M, Komrokji R, Safa M Am. J. Clin. Oncol. 2009 Jun 32 3 286-90
- Oxaliplatin-induced immune mediated thrombocytopenia.
- Beg MS, Komrokji RS, Ahmed K, Safa MM Cancer Chemother. Pharmacol. 2008 Oct 62 5 925-7
Honors & Awards
- Resident Teacher Award
University of Cincinnati (2008)
- American Association for Cancer Research (2011)
- American Society of Clinical Oncology (2008)